Navigation Links
Varian Medical Systems Acquires Assets of IKOEmed and IKOEtech; Acquisition to Add Software for Accelerating Radiotherapy Treatment Planning
Date:6/25/2009

PALO ALTO, Calif., June 25 /PRNewswire-FirstCall/ -- Varian Medical Systems, Inc., (NYSE: VAR) today announced it has acquired the assets of Houston-based IKOEmed and IKOEtech, privately-owned suppliers of software used in the planning of radiotherapy and radiosurgery treatments. The acquisition enables Varian to offer hospitals and clinics an additional software tool to automate and accelerate the most time-consuming portion of the treatment planning process. Varian is paying approximately $2.2 million plus an additional amount based on achievement of specified milestones to acquire the IKOE assets.

The software is designed to achieve greater than 50 percent reduction in the contouring portion of the radiotherapy treatment planning process, which typically takes anywhere from 30 minutes to 4 hours. It automates the contouring process by matching patient images with pre-contoured images from an expert database created by renowned radiation oncologists. This eliminates the need for clinicians to manually outline between 10 and 20 organs in each of anywhere from 100 to 200 images of a patient's disease site.

"This is another important step in our ongoing initiative to make cancer treatments better, faster, easier, and more cost effective," said Tim Guertin, president and CEO of Varian Medical Systems. "This new tool should save a lot of time in planning for complex cases, particularly in cancers of the head and neck and lymph systems." The IKOE software, which has FDA 510(k) clearance, complements Varian's existing segmentation tools currently used to automate planning for prostate, breast, and lung treatments.

Varian will sell the software initially in the U.S. as a standalone product that will work with most radiotherapy treatment planning software products in the industry. The company plans to integrate it with its global market leading Eclipse(TM) treatment planning software for radiotherapy, radiosurgery, and brachytherapy.

Varian anticipates the acquisition be neutral to earnings for the company in the current fiscal year and accretive thereafter. "We expect that our worldwide sales, service, and support network will contribute to faster and deeper market penetration for these software products," Guertin said. The IKOE software is now installed in about 20 sites, primarily in the U.S.

Four IKOE employees and consultants are being offered jobs with Varian to support the product at Varian facilities in the U.S.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, Europe, and China and approximately 79 sales and support offices around the world. For more information, visit http://www.varian.com.

Forward Looking Statements:

Except for historical information, this news release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry and market outlook, including customer demand and acceptance of products or technology for radiotherapy and radiosurgery; the outlook for certain geographic regions and markets; growth drivers; and the outlook for Varian's our orders, sales, backlog, or earnings growth; future financial results and any statements using the terms "will," "expect," "anticipates," "enable," "should," "plans," or similar statements are forward-looking statements that involve risks and uncertainties that could cause our actual results to differ materially from those anticipated. Such risks and uncertainties include the ability to effectively integrate the software of IKOEmed and IKOEtech into Varian product offerings and sales and marketing operations, the ability to retain the services of key IKOE personnel; demand for our and IKOE's products; our ability to develop and commercialize new products; the impact of competitive products and pricing; our ability to maintain or increase operating margins; our ability to protect our intellectual property; the risk of operations interruptions due to events beyond our control; and the other risks listed from time to time in our filings with the Securities and Exchange Commission. We assume no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

    FOR INFORMATION CONTACT:
    Varian Medical Systems
    Spencer Sias, (650) 424-5782


'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
3. Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery
4. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
5. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
6. New SPE Cation Exchange Technology From Varian Simplifies Extraction of Basic Compounds
7. Varian Medical Systems Sponsors Special Broadcast of The Group Room(R), a Live Radio Talkshow About Cancer
8. Varian, Inc. Reports First Quarter 2008 Results
9. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... chronic diseases, announced that Catherine Bovenizer , ... Officer (CFO), effective today. Ms. Bovenizer ... in financial management for a variety of public ... recently, Ms. Bovenizer was the Vice President of ...
(Date:12/5/2016)... Research and Markets has announced the ... Technologies, Markets and Companies" to their offering. ... , , ... human genome variations, development of sequencing technologies, and their applications. ... companies developing them. Various applications of sequencing are described including ...
(Date:12/4/2016)... DIEGO , Dec. 3, 2016  In five ... of Hematology (ASH) Annual Meeting and Exposition in ... biomedical engineering methods to improve the delivery of life-saving ... These new methods are designed to carry therapies directly ... needed most, which could provide a substantial advantage over ...
(Date:12/2/2016)... Dec. 2, 2016  The Multiple Myeloma Research Foundation ... MMRF CoMMpass Study SM —the largest and most comprehensive ... in multiple myeloma—will be presented at the 58 th ... Exposition in San Diego from ... treatment strategies, as well as identify pathways and targets ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ... Systems) ... largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of an ...
(Date:11/22/2016)... -- According to the new market research report "Biometric System ... Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and ... expected to grow from USD 10.74 Billion in 2015 to reach USD ... 2022. Continue Reading ... ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
Breaking Biology News(10 mins):